Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock

Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common
Stock
PR Newswire
SAN FRANCISCO, Jan. 21, 2014
SAN FRANCISCO, Jan. 21, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:
NKTR) ("Nektar") today announced that it has commenced an underwritten public
offering of 8,500,000 shares of its common stock. In connection with this
offering, Nektar will also grant to the underwriters a 30-day option to
purchase up to an additional 1,275,000 shares of common stock. J.P.Morgan and
Jefferies are acting as joint book-running managers in the offering. The
offering is subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual size or
terms of the offering.
Nektar intends to use the net proceeds from this offering for general
corporate purposes including research and development funding and working
capital.
The securities described above are being offered by Nektar pursuant to an
effective shelf registration statement (including a base prospectus) filed
with the Securities and Exchange Commission ("SEC"). Before you invest, you
should read the base prospectus in the registration statement and related
preliminary prospectus supplement that Nektar has filed with the SEC for more
complete information about Nektar and this offering. The preliminary
prospectus supplement and accompanying base prospectus are available for free
by visiting EDGAR on the SEC's website located at www.sec.gov. Copies of the
preliminary prospectus supplement and accompanying base prospectus, when
available, may also be obtained from the offices of J.P.Morgan Securities
LLC, attention Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York, NY 11717, or telephone: 866-803-9204 or Jefferies LLC,
Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New
York, NY, or telephone: 877-547-6340 or by emailing
Prospectus_Department@Jefferies.com.
This press release does not constitute an offer to sell, or the solicitation
of an offer to buy these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
SOURCE Nektar Therapeutics
Website: http://www.nektar.com
Contact: Jennifer Ruddock, 415-482-5585